Table 3 Comparison between low and normal-high FT4 groups in patients with COVID-19 presenting with NTI

Age, y, M (IQR)

64.5 (41.75, 71.75)

70 (62.25, 79.75)

0.077

Gender (female n, %)

8 (50%)

61 (45.52%)

0.734

Critical illness (n, %)

9 (56.25%)

57 (42.54%)

0.296

Mortality (n, %)

8 (50%)

34 (25.37%)

0.038

WBC, *10^9/L, M (IQR)

10.35 (8.34, 26.87)

10.92 (7.79, 16.65)

0.455

LC, *10^9/L, M (IQR)

1.175 (0.72, 1.75)

1.48 (0.98, 1.87)

0.284

CRP, mg/L, M (IQR)

71.75 (37.65, 225.1)

95.3 (42.675, 172.2)

0.886

Ferroprotein, ug/L, M (IQR)

1782.2 (767.95, 7462.3)

1221.9 (618.6, 2303.05)

0.214

PCT, ng/mL, M (IQR)

0.97 (0.15, 8.56)

0.17 (0.08, 0.87)

0.021

ALT, U/L, M (IQR)

47 (23.75, 76)

43 (21.25, 73.75)

0.976

AST, U/L, M (IQR)

91.5 (38.25, 221.25)

43 (26, 68.75)

0.025

ALB, g/L, M (IQR)

32 (29.55, 34.55)

35.7 (30.7, 39.3)

0.277

LDH, U/L, M (IQR)

347 (248, 405)

216.5 (177, 272.5)

0.066

CR, umol/L, M (IQR)

124.5 (82.5, 214.5)

87 (66.5, 114)

0.029

UREA, mmol/L, M (IQR)

17.9 (5.73, 28.5)

8.55 (5.7, 14.33)

0.06

cTnI, pg/mL, M (IQR)

287 (8.7, 803.4)

15.9 (6.4, 139)

0.189

D2D, ug/mL FEU, M (IQR)

7.51 (1.85, 21)

5.24 (1.39, 18.94)

0.479

FT3, pmol/L, M (IQR)

2.36 (1.8, 2.795)

2.69 (2.3625, 2.91)

0.027

FT4, pmol/L, M (IQR)

10.55 (9.01, 11.69)

16.75 (14.38, 18.46)

/

TSH, uIU/mL, M (IQR)

1.82 (0.62, 2.15)

0.897 (0.41, 1.79)

0.235